Under Priority Review status, the FDA accepts TG Therapeutics’ (TGTX +4.9%) marketing application for umbralisib for the treatment of patients with previously treated marginal zone lymphoma (MZL) who have received at least one prior anti-CD20 based regimen and follicular lymphoma (FL) who have received at least two prior systemic therapies.
The agency’s action date is February 15, 2021.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.